U.S. Markets closed
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • Dow 30

    32,774.41
    -58.13 (-0.18%)
     
  • Nasdaq

    12,493.93
    -150.53 (-1.19%)
     
  • Russell 2000

    1,912.89
    -28.31 (-1.46%)
     
  • Crude Oil

    90.60
    -0.16 (-0.18%)
     
  • Gold

    1,811.50
    +6.30 (+0.35%)
     
  • Silver

    20.52
    -0.09 (-0.46%)
     
  • EUR/USD

    1.0217
    +0.0029 (+0.2861%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2074
    +0.0004 (+0.0302%)
     
  • USD/JPY

    135.1090
    +0.1390 (+0.1030%)
     
  • BTC-USD

    23,109.78
    -849.06 (-3.54%)
     
  • CMC Crypto 200

    536.72
    -20.64 (-3.70%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,999.96
    -175.94 (-0.62%)
     

Why You Should Care About Edwards Lifesciences' (NYSE:EW) Strong Returns On Capital

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. That's why when we briefly looked at Edwards Lifesciences' (NYSE:EW) ROCE trend, we were very happy with what we saw.

Understanding Return On Capital Employed (ROCE)

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Edwards Lifesciences, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.21 = US$1.6b ÷ (US$8.5b - US$1.0b) (Based on the trailing twelve months to December 2021).

So, Edwards Lifesciences has an ROCE of 21%. In absolute terms that's a great return and it's even better than the Medical Equipment industry average of 8.1%.

View our latest analysis for Edwards Lifesciences

roce
roce

In the above chart we have measured Edwards Lifesciences' prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Edwards Lifesciences here for free.

The Trend Of ROCE

We'd be pretty happy with returns on capital like Edwards Lifesciences. The company has consistently earned 21% for the last five years, and the capital employed within the business has risen 88% in that time. Returns like this are the envy of most businesses and given it has repeatedly reinvested at these rates, that's even better. You'll see this when looking at well operated businesses or favorable business models.

The Key Takeaway

In short, we'd argue Edwards Lifesciences has the makings of a multi-bagger since its been able to compound its capital at very profitable rates of return. And the stock has done incredibly well with a 235% return over the last five years, so long term investors are no doubt ecstatic with that result. So while investors seem to be recognizing these promising trends, we still believe the stock deserves further research.

On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation on our platform that is definitely worth checking out.

Edwards Lifesciences is not the only stock earning high returns. If you'd like to see more, check out our free list of companies earning high returns on equity with solid fundamentals.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.